Page 5,632«..1020..5,6315,6325,6335,634..5,6405,650..»

stem cells presentation and brief introduction – Video

Posted: Published on March 2nd, 2013

stem cells presentation and brief introduction stem cells presentation and brief introduction, to know more about all possibilities from stem cell treatment visit http://www.stemrx.in By: StemRx BioScience … Continue reading →

Comments Off on stem cells presentation and brief introduction – Video

Osiris Therapeutics Establishes Direct Sales Force for Grafix®

Posted: Published on March 2nd, 2013

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading company focused on developing and marketing stem cell products to treat serious medical conditions, announced today the introduction of a proprietary, direct sales force for Grafix, a premium cellular repair matrix for serious wounds including diabetic foot ulcers. The team of biologics sales professionals will initially be deployed in 10 major metropolitan areas throughout the United States and is expected to double over the coming year. Field representatives are supported by the Osiris medical affairs staff and a world-class team of stem cell scientists. This organization will enable Osiris to offer wound care practitioners a uniquely sophisticated service, only available from the cell therapy leader with 20 years of experience in the space. "The decision to take Grafix into the wound care market with our own proprietary sales force was based upon a number of factors, including meaningful progress being made in reimbursement and favorable market dynamics," said Frank Czworka, Executive Director, Wound Care of Osiris Therapeutics. "However, the primary driver behind this initiative is the positive clinical results our physicians and surgeons are experiencing with Grafix. We continue to invest significant resources in Grafix to further demonstrate the clinical benefit … Continue reading →

Comments Off on Osiris Therapeutics Establishes Direct Sales Force for Grafix®

FRC’s Dr. David Prentice Congratulates Kansas Senate for Passing Ethical Stem Cell Therapy Bill

Posted: Published on March 1st, 2013

WASHINGTON, March 1, 2013 /PRNewswire-USNewswire/ --Family Research Council (FRC) Senior Fellow Dr. David Prentice, a native Kansan, congratulated the Kansas state senate for passing S.B. 199, a bill that would establish the Midwest Stem Cell Therapy Center, a regional hub to advance and deliver adult and cord blood stem cell therapies to patients and serving as a resource for adult and cord blood stem cells for therapies. The Center would also inform professionals and the public about such therapies. (Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO) Dr. Prentice, a cell biologist who was selected by George W. Bush's Council on Bioethics to write a comprehensive review of adult stem cell research in 2004, testified before the Kansas Senate Committee on Public Health and Welfare in support of S.B. 199 on Feb. 25. Dr. Prentice additionally serves as adjunct professor of molecular genetics at the John Paul II Institute at the Catholic University of America, and formerly served as professor of life sciences at Indiana State University and adjunct professor of medical and molecular genetic at Indiana University School of Medicine. The bill will now go to the Kansas House of Representatives for consideration. In his testimony Dr. Prentice said: "There are significant opportunities right now … Continue reading →

Posted in Cell Therapy | Comments Off on FRC’s Dr. David Prentice Congratulates Kansas Senate for Passing Ethical Stem Cell Therapy Bill

Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphere™ Cell Therapy

Posted: Published on March 1st, 2013

SALT LAKE CITY, Feb. 28, 2013 /PRNewswire/ --Discgenics announces the successful completion of an animal study demonstrating safety and efficacy of its novel therapy for reducing back pain caused by degenerative disc disease. This product, known as Injectable Discosphere Cell Therapy (IDCT), features Discgenics' patented, allogeneic, human disc-derived stem cell technology. The study showed that after one injection of IDCT in degenerated discs there was a restoration of disc height and tissue architecture, while noting no inflammatory response. Discgenics CEO Flagg Flanagan said, " We are very encouraged by the results of the small animal pilot study as it shows the initial safety and efficacy of IDCT, which is produced from adult human disc-derived stem cells.We are optimistic that these early results will be indicative of our therapy's performance in further animal studies and will accelerate us toward human clinical studies and, ultimately, to an FDA cleared product.We believe this technology will revolutionize the way back pain is treated." Discgenics is currently conducting further studies of safety and efficacy in multiple animal species to support future scientific publications and for use in gaining regulatory clearance. About Discgenics, Inc. Discgenics is a privately funded spinal therapeutics company that is utilizing adult … Continue reading →

Posted in Cell Therapy | Comments Off on Discgenics Successfully Completes Pilot Efficacy Study of Injectable Discosphere™ Cell Therapy

DrugRisk Update: Mirena Use Drops As Court to Decide Fate of Lawsuits

Posted: Published on March 1st, 2013

New York, NY (PRWEB) March 01, 2013 The birth control safety advocates at DrugRisk.com are alerting women using the IUD contraceptive Mirena of updated information on the site showing use of the devices dropped for the last part of 2012, as a court gets set to decide the fate of growing patient injury claims. The mission of DrugRisk is to improve consumer safety by providing the latest drug warnings, recalls, studies and legal news. Many visitors look for legal news to learn if other patients are having similar side effects and whether they need legal advice, explains DrugRisk representative Ryan Mayer. DrugRisk contains information showing the FDA has received more than 47,000 AERS adverse event reports for complications by patients using the Mirena IUD.* Of these, 5079 involved dislocation and 1421 involved device migration, which can damage the uterine wall or other organs.* Over 6% of patients required hospitalization or surgery. Now, the latest financial reports from Bayer indicate sales of Mirena dropped 14% in the 4th quarter of 2012, from $206 million to $177 million, compared to the previous year.** DrugRisk has discovered injury claims from patients may be growing as well. With the number of patients filing a … Continue reading →

Posted in Drug Side Effects | Comments Off on DrugRisk Update: Mirena Use Drops As Court to Decide Fate of Lawsuits

DrugRisk Update: Bayer Pays Approx. $1 Billion So Far In Yaz Settlements

Posted: Published on March 1st, 2013

Dallas, TX (PRWEB) March 01, 2013 The birth control safety advocates at DrugRisk.com are alerting those who have taken the oral contraceptives Yaz or Yasmin of new information added to the site which shows Bayer continues to compensate victims of blood clot-type injuries related to the drugs. The goal of DrugRisk is to improve patient safety through education of the latest drug warnings, recalls, studies and litigation news. Many visitors to the site are concerned over blood clot side effects and want to know if Bayer is still compensating victims, explains DrugRisk representative Ryan Mayer. The resource center contains studies from the British Medical Journal and FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.* Now, DrugRisk has obtained the latest financial information from Bayer, which shows the company faces as many as 13,600 total claims relating to Yaz side effects.** So far, they have spent approximately $1 billion to settle around 4,800 claims involving blood clot injuries like deep vein thrombosis (DVT) or Yaz pulmonary embolism.** The records also indicate Bayer will continue to evaluate blood clot claims … Continue reading →

Posted in Drug Side Effects | Comments Off on DrugRisk Update: Bayer Pays Approx. $1 Billion So Far In Yaz Settlements

Lawmakers eyed, too, in drug test bill

Posted: Published on March 1st, 2013

Published: 2/28/2013 9:30 PM | Last update: 3/1/2013 10:48 AM Sen. Jay Emler, R-Lindsborg, was one of two Republicans voting Thursday against drug-testing Senate Bill No. 149. It sailed through on a 31-8 vote. The bill goes to the House for consideration. "Many people from my district have asked me if legislation that required drug testing for welfare recipients could be brought forward in Kansas. I don't think taxpayers should be subsidizing drug addictions," Love said in a statement. "More importantly, I have seen the ill effects of those on welfare, who are fathers and mothers, who use the welfare money for drugs, and also how that negatively impacts their families. While some feel we are being passionate, some of our welfare policies are really promoting a culture of poverty," Love wrote. Drug screening can be ordered "when reasonable suspicion exists" that an applicant or recipient of cash aid is unlawfully using a controlled substance, the bill states. Opponents expressed concern during a prior committee hearing that state officials could presume welfare recipients were on drugs. Senate Majority Leader Terry Bruce said the legislation "provides the help and services those struggling with drug addiction need." For those failing the drug … Continue reading →

Posted in Drug Dependency | Comments Off on Lawmakers eyed, too, in drug test bill

Drug-test bill eyes lawmakers as well

Posted: Published on March 1st, 2013

Published: 2/28/2013 9:30 PM | Last update: 3/1/2013 10:48 AM Sen. Jay Emler, R-Lindsborg, was one of two Republicans voting Thursday against drug-testing Senate Bill No. 149. It sailed through on a 31-8 vote. The bill goes to the House for consideration. "Many people from my district have asked me if legislation that required drug testing for welfare recipients could be brought forward in Kansas. I don't think taxpayers should be subsidizing drug addictions," Love said in a statement. "More importantly, I have seen the ill effects of those on welfare, who are fathers and mothers, who use the welfare money for drugs, and also how that negatively impacts their families. While some feel we are being passionate, some of our welfare policies are really promoting a culture of poverty," Love wrote. Drug screening can be ordered "when reasonable suspicion exists" that an applicant or recipient of cash aid is unlawfully using a controlled substance, the bill states. Opponents expressed concern during a prior committee hearing that state officials could presume welfare recipients were on drugs. Senate Majority Leader Terry Bruce said the legislation "provides the help and services those struggling with drug addiction need." For those failing the drug … Continue reading →

Posted in Drug Dependency | Comments Off on Drug-test bill eyes lawmakers as well

STOCKS NEWS EUROPE-Lundbeck rises 3 pct after FDA drug approval

Posted: Published on March 1st, 2013

Danish drug firm Lundbeck (Copenhagen: LUN.CO - news) rises 3 percent after the U.S. Food and Drug Administration approves its injectable form of Abilify, a treatment for schizophrenia to be sold with Japan's Otsuka. Lundbeck also outperforms a 0.4 percent gain on Denmark's benchmark OMX Copenhagen 20 equity index. The approval is the second small boost for the firm in two days after European regulators gave their nod for Lundbeck to start selling its new drug to for alcohol dependency. Analysts said both approvals were mostly priced in but the firm needs all the good news it can get as it fights falling sales because of generic competition, and heavy investments as it works to bring new products to the market. The stock fell to its lowest in over 12 years in December but has been rising steadily as investors consider it to be oversold given its promising pipeline of products. For more double click on Reuters messaging rm://balazs.koranyi.thomsonreuters.com@reuters.net Continue reading here: STOCKS NEWS EUROPE-Lundbeck rises 3 pct after FDA drug approval … Continue reading →

Posted in Drug Dependency | Comments Off on STOCKS NEWS EUROPE-Lundbeck rises 3 pct after FDA drug approval

Menopause Drugs from Depomed, Hisamitsu Offer Benefits

Posted: Published on March 1st, 2013

Drugs being developed by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) to ease menopausal hot flashes yielded inconsistent results in trials that call into question how meaningful the benefits would be, regulators said. Depomeds gabapentin and Hisamitsus paroxetine mesylate were shown to help women avoid sudden feverish feelings linked to menopause, staff at the Food and Drug Administration said in a report today. The concern is that the reduction in severity and frequency of the flashes varied widely in clinical trials. Each drug, non-hormonal alternatives to the existing medicines, will be discussed on March 4 by agency advisers. Companies have been looking to give women more choices in menopause therapies after hormone treatments were found to increase the risk of breast cancer, heart attack and stroke. Theres a real need for an approved product so women who dont want to use hormones dont have to suffer in silence, Michael Sweeney, chief medical officer for Menlo Park, California-based Depomed, said in a telephone interview. Hot flashes affect about 32 million women in the U.S. and 40 percent choose not to use hormones or arent good candidates for them, Depomed said. The FDA is scheduled to decide on Depomeds pill by … Continue reading →

Posted in Drugs | Comments Off on Menopause Drugs from Depomed, Hisamitsu Offer Benefits

Page 5,632«..1020..5,6315,6325,6335,634..5,6405,650..»